Gene profiling can single out the worst cases of multiple myeloma and guide therapySeptember 19, 2007ATLANTA - Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide therapy in the future. Researchers followed 532 multiple myeloma patients for seven years after blood stem cell transplant to create a genetic profile to chart the severity of the disease. The team determined that the activity of as few as 17 genes could mean the difference between high or low risk for a poor prognosis. They present their data today at the American Association for Cancer Research's second International Conference on Molecular Diagnostics in Cancer Therapeutic Development, in Atlanta, Ga. "There are enormous differences between how different people fare with multiple myeloma. While most do very well others have a highly aggressive form of the disease and this is not recognized well with current prognostic variables," said lead researcher John D. Shaughnessy, Jr., Ph.D., a professor of medicine at the Myeloma Institute for Research and Therapy. "If we can categorize a patient's risk early, we can better guide that patient toward therapies that might be more effective for them based on the genetic profile of the disease."
Multiple myeloma is a cancer affecting the blood plasma cells in bone marrow that produce antibodies. Nearly 14,600 new cases of multiple myeloma occur each year in the United States. The disease is most often treated through the use of high dose chemotherapy and peripheral blood-derived stem cell support. While multiple myeloma often responds well to initial treatment, it often becomes drug resistant and patients are prone to relapse. According to the researchers, survival varies greatly between low-risk and high-risk patients. "At 24 months, about 90 percent of low-risk patients will be alive, whereas about 50 percent of the high-risk patients have succumbed to the disease," said Fenghuang Zhan M.D., Ph.D., of the University of Arkansas for Medical Sciences. To understand the possible molecular mechanisms driving initiation and progression of multiple myeloma, the researchers launched a large-scale, longitudinal study to categorize the differences in gene expression patterns, that is, which genes are activated and inactivated, in relatively indolent versus aggressive disease. Using purified tumor cells taken from 532 newly diagnosed patients who went on to receive uniform therapy, the researchers screened over 54,000 genes across the human genome for signs that might relate to multiple myeloma survival estimates. About 13 percent of all the patients they studied exhibited a genetic pattern that fit into the high-risk category, a frequency that rose to 76 percent among relapsed patients. "The observation of an increase in the gene expression risk score among relapsed patients provides evidence that there are likely to be small subsets of high-risk cells even in patients with low risk disease, and that current therapeutics are sub-optimal in that they kill off the low-risk cells, leaving behind cells that exhibit a high-risk genetic profile," Shaughnessy said. Currently, the researchers have experiments underway to definitively prove this concept. Initially, the researchers identified 70 genes linked to early cancer-related death, although further analysis narrowed that number to 17. Remarkably, about 30 percent of the genes that predict high risk are found on chromosome 1, enough so that Shaughnessy recognized a trend among the genes, based on where they map on each chromosome in the human genome. The majority of genes that were up-regulated - or over-produced - in high-risk patients mapped to the long arm of chromosome 1, while the majority of genes that were down-regulated - or suppressed - mapped to the short arm of the same chromosome. "Together these data suggest that defects in chromosome 1 may be directly related to the acquisition of higher risk in patients with multiple myeloma," Shaughnessy said. "Gene expression profiles have now provided us with signposts that help us risk stratify patients and tailor therapies accordingly." "Importantly, these data may provide researchers with key insights into molecular mechanisms driving disease severity which might be the target of future therapies," Shaughnessy said. American Association for Cancer Research | |||||||||||||||||||||
|
Related Myeloma Current Events and Myeloma News Articles The miseries of allergies just may help prevent some cancers, study finds There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study. Supercomputer provides massive computational boost to biomedical research at TGen In less time than the blink of an eye, the Translational Genomics Research Institute's new supercomputer at Arizona State University can do operations equal to every dollar in the recent Wall Street bailout. On the trail of a targeted therapy for blood cancers nvestigators from the Herman B Wells Center for Pediatric Research at the Indiana University School of Medicine are focusing on a family of blood proteins that they hope holds a key to decreasing the toxic effects of chemotherapy in children and adults. Mayo researchers explore issues related to multiple myeloma treatment Multiple myeloma (MM) is a cancer of plasma cells that affects approximately 3 in 100,000 people each year. Although there is no cure for this disease, researchers have developed treatments that help relieve pain, control complications, and slow the progress of MM in many patients. VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma. Researchers discover how rheumatoid arthritis causes bone loss Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry. Clinical study shows biological and clinical activity in relapsed leukemia patients Finbarr Cotter, M.D., Ph.D., Professor of the Institute of Cell and Molecular Science at Barts and The London School of Medicine, today presented in an oral session "Clinical Caspase Activation in CLL by GCS-100: a Phase 2 Study" at the 10th International Conference on Malignant Lymphoma (10-ICML). OHSU Discovery May Lead to Early Cancer Detection OHSU pancreatic cancer expert Brett Sheppard, M.D., and colleagues in the OHSU Oregon Stem Cell Center, have developed antibodies that recognize pancreatic cancer; Sheppard is presenting these findings this week during Digestive Disease Week in San Diego. Immune system pathway identified to fight allergens, asthma For the first time, researchers from the University of Pittsburgh School of Medicine have identified genetic components of dendritic cells that are key to asthma and allergy-related immune response malfunction. U of Minnesota study finds thalidomide shows promise for treatment of recurrent ovarian cancer Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a study led by a University of Minnesota Cancer Center researcher. More Myeloma Current Events and Myeloma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||